Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction

20201,250 citationsJournal Articlebronze Open Access

Authors

Paul W. Armstrong · Canadian VIGOUR Centre

Burkert Pieske · Charité - Universitätsmedizin Berlin

Kevin J. Anstrom · Duke University

Justin A. Ezekowitz · Canadian VIGOUR Centre

Adrian F. Hernandez · Duke University

Javed Butler · Jackson Memorial Hospital

Carolyn S.P. Lam ·

Abstract

Among patients with high-risk heart failure, the incidence of death from cardiovascular causes or hospitalization for heart failure was lower among those who received vericiguat than among those who received placebo. (Funded by Merck Sharp & Dohme [a subsidiary of Merck] and Bayer; VICTORIA ClinicalTrials.gov number, NCT02861534.).

Topics & Keywords

Heart Failure Treatment and Management Cardiovascular Function and Risk Factors Diabetes Treatment and Management

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 382, Issue 20, pp. 1883-1893

DOI: 10.1056/nejmoa1915928

Field-Weighted Citation Impact: 118.05